Sanofi SA (SNY)

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.

U.S. stock futures point higher as oil prices rally; Canada's autoworkers' union and GM make little progress in contract talks ahead of a Monday deadline.

And we'll get FOMC and BoJ then.

Sanofi and its specialty care global business unit Sanofi Genzyme announced today positive new six-year investigational data from the extension study of Lemtrada ® (alemtuzumab) in patients with relapsing...

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced positive new real-world data from the Phase 4 Teri-PRO (Patient Reported Outcomes) study of Aubagio ®  (teriflunomide), a...

- Joshua Riff, M.D., Named Chief Executive Officer -

The EpiPen controversy makes this stock a shot in the dark.

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

How does technical analysis stack up to John Paulson's stock picking strategy?

Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.

TGNA, AMRK, FBRC, FLO and SNY were all recently downgraded by TheStreet's Quant Ratings.

Clinton goes after the drug companies again -- for starters.

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

Here are 10 stocks hedge fund manager John Paulson has been buying lately, either initiating new stakes or upping his holdings significantly.

Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

PFE is trading up on the announcement, and the deal should add to earnings in 2017.

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

The sector seems to be rebounding after tumbling by more than 40%.

The alternate reality mobile gaming app has been downloaded over 75 million times in less than a month.